SAN DIEGO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Mereo BioPharma Group plc. (NASDAQ: MREO) American Depository Shares ("ADS") between June 5, 2023 and December 26, 2025. Mereo is a biopharmaceutical company focused on the development of therapeutics for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegation ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Mereo BioPharma To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Mereo between June 5, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - February 9 ...

New York, New York--(Newsfile Corp. - February 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023, and December 26, 2025. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 6, 2026.SO WHAT: If you purchased Mereo securities during the Class Period you may ...

PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”) on behalf of investors who purchased Mereo American Depositary Shares (ADS) during the period from June 5, 2023 through December 26, 2025 (the “Class Period”). Investor Deadline: Investors who purchased Mereo securities during the Class Period may, no later than  April 6, 2026, seek to ...

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc for alleged violations of securities laws, specifically related to misleading statements about its clinical programs [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from June 5, 2023, to December 26, 2025, with a deadline for lead plaintiff appointments set for April 6, 2026 [2]. - The complaint alleges that Mereo made false and misleading statements regarding its Phase 3 ORBIT and COSMIC programs, which did not meet their endpoints compared to placebo or bisphosphonate control groups [2]. Group 2: Investor Participation - Shareholders who purchased MREO shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although this is not necessary to participate in any recovery [2][3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Mereo BioPharma Group plc for alleged violations of federal securities laws related to misleading statements about its clinical programs [4]. Group 1: Legal Investigation - The law firm is encouraging Mereo investors who suffered losses exceeding $50,000 to contact them for discussing legal options [1]. - A federal securities class action has been filed against Mereo, with a deadline of April 6, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Mereo and its executives made false statements and failed to disclose the true state of the Phase 3 ORBIT and COSMIC programs, which did not meet their primary endpoints [4]. Group 2: Firm Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. - The firm has offices in New York, Pennsylvania, California, and Georgia, indicating a broad operational reach [3]. Group 3: Whistleblower Encouragement - The firm is also seeking information from whistleblowers, former employees, shareholders, and others regarding Mereo BioPharma's conduct [6].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Shares of Mereo BioPharma Group plc, covering the period from June 5, 2023, to December 26, 2025, due to alleged misleading statements regarding the company's clinical programs [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma Group made false and/or misleading statements about the Phase 3 ORBIT and COSMIC programs, which did not meet their primary endpoints of reducing annualized clinical fracture rates compared to control groups [5]. - Investors who purchased Mereo BioPharma Group securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly. The deadline to serve as lead plaintiff is April 6, 2026 [3][6]. - It is noted that no class has been certified yet, and investors are not represented by counsel unless they retain one [7].

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc for misleading statements regarding its Phase 3 clinical programs, potentially affecting investors who purchased American Depositary Shares between June 5, 2023, and December 26, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma made false or misleading statements about the Phase 3 ORBIT and COSMIC programs, which did not meet their primary endpoints of reducing annualized clinical fracture rates compared to control groups [5]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Investors wishing to join the class action can do so by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by April 6, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements, ranking highly in the industry since 2013 [4].

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Mereo securities between June 5, 2023 and December 26, 2025, both ...

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose the true state of the Phase 3 ORBIT and COSMIC programs; neither of which hit its prima ...